Reshma Kewalramani sold $7.8M of Vertex Pharmaceuticals Incorporated (VRTX)

Executed Nov 8 2024, disclosed Nov 12 2024, 4 days later.

Value, as filed

$7.8M

15,198 sh × $515.00

Executed

Nov 8 2024

the trade date, as filed

Disclosed

Nov 12 2024

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

purchases only

Returns are measured on stock purchases only.

The filer

RK Reshma Kewalramani CEO & President profile →

Reshma Kewalramani (CEO & President) filed 1 Form 4 report in the trailing twelve months (0 purchases, 1 sale), most often in Vertex Pharmaceuticals Incorporated (VRTX). The largest single filing was $19.7M of VRTX (39,880 sh across 12 lots, as filed), executed Feb 27.

The name

VRTX Vertex Pharmaceuticals Incorporated VRTX · Healthcare · 90 filings in 24 months ticker →

Healthcare · Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Reshma Kewalramani in VRTX

VRTXSALE Vertex Pharmaceuticals Incorporated $19.7M
39,880 sh across 12 lots
Exec Feb 27
Filed Mar 3 · 5:30 PM ET VRTXPURCHASE Vertex Pharmaceuticals Incorporated $3.9M
10,000 sh across 2 lots
Exec Aug 6 2025
Filed Aug 7 2025 · 4:23 PM ET